These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34090354)

  • 1. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification.
    Yamamoto M; Kobayashi T; Hashimoto M; Kuroda S; Kawaoka T; Aikata H; Chayama K; Ohdan H
    BMC Cancer; 2021 Jun; 21(1):668. PubMed ID: 34090354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH
    Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Kitano M; Nishida N; Kudo M
    Oncology; 2015; 89 Suppl 2():47-52. PubMed ID: 26584036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
    Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
    Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
    Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
    Kudo M; Arizumi T; Ueshima K; Sakurai T; Kitano M; Nishida N
    Dig Dis; 2015 Oct; 33(6):751-8. PubMed ID: 26488473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma.
    Wang JH; Kee KM; Lin CY; Hung CH; Chen CH; Lee CM; Lu SN
    J Gastroenterol Hepatol; 2015 Feb; 30(2):358-63. PubMed ID: 25088668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ida H; Sakurai T; Kitano M; Nishida N; Kudo M
    Dig Dis; 2016; 34(6):671-678. PubMed ID: 27750236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
    Kuo MJ; Mo LR; Chen CL
    BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.
    Hu KS; Tang B; Yuan J; Lu SX; Li M; Chen RX; Zhang L; Ren ZG; Yin X
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1984-1991. PubMed ID: 30932246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
    Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
    AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.
    Zhaohui Z; Shunli S; Bin C; Shaoqiang L; Yunpeng H; Ming K; Lijian L; Gang PB
    Cancer Res Treat; 2019 Jan; 51(1):65-72. PubMed ID: 29510616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Kajiwara A; Noda Y; Kamachi N; Okamura S; Nakano M; Kuromatsu R; Kawaguchi T; Koga H; Torimura T
    Oncology; 2021; 99(12):756-765. PubMed ID: 34518483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.
    Weinmann A; Koch S; Sprinzl M; Kloeckner R; Schulze-Bergkamen H; Düber C; Lang H; Otto G; Wörns MA; Galle PR
    Liver Int; 2015 Feb; 35(2):591-600. PubMed ID: 25290314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
    Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
    Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.